Memantine inhibits β-amyloid aggregation and disassembles preformed β-amyloid aggregates

Biochemical and Biophysical Research Communications

Volumn 493, Issue 1, 2017, Pages 158-163

  Takahashi Ito, Kaori ^a   Makino, Mitsuhiro ^a   Okado, Keiko ^a   Tomita, Taisuke ^b  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Alzheimer's disease; A aggregation; Memantine; amyloid

Indexed keywords

AMANTADINE; AMYLOID; AMYLOID BETA PROTEIN[1-42]; MEMANTINE; THIOFLAVINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PROTEIN BINDING;

AMYLOIDOSIS; ANIMAL CELL; ARTICLE; BRAIN LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DIMERIZATION; ULTRASTRUCTURE;

AMYLOID BETA-PEPTIDES; DIMERIZATION; MEMANTINE; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 85029525450     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.09.058     Document Type: Article

References (38)

1. Selkoe, D.J., Schenk, D., Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43 (2003), 545–584.
2. Selkoe, D.J., Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8 (2016), 595–608.
3. Tomita, T., Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. Adv. Biol. Regul. 64 (2017), 33–38.
4. Kikuchi, K., Kidana, K., Tatebe, T., et al. Dysregulated metabolism of the amyloid-β protein and therapeutic approaches in Alzheimer disease. J. Cell Biochem., 2017 in press.
5. Iwatsubo, T., Odaka, A., Suzuki, N., et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 (1994), 45–53.
6. Tomita, T., Maruyama, K., Saido, T.C., et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 2025–2030.
7. Iizuka, T., Shoji, M., Harigaya, Y., et al. Amyloid β-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. Brain Res. 702 (1995), 275–278.
8. Parvathy, S., Davies, P., Haroutunian, V., et al. Correlation between Aßx-40-, Aßx-42- and Aßx-43-containing amyloid plaques and cognitive decline. Arch. Neurol. 58 (2001), 2025–2032.
9. Welander, H., Frånberg, J., Graff, C., et al. Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains. J. Neurochem. 110 (2009), 697–706.
10. Saito, T., Suemoto, T., Brouwers, N., et al. Potent amyloidogenicity and pathogenicity of Aβ43. Nat. Neurosci. 14 (2011), 1023–1032.
11. Saido, T.C., Iwatsubo, T., Mann, D.M., et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14 (1995), 457–466.
12. Hendriks, L., van Duijn, C.M., Cras, P., et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat. Genet. 1 (1992), 218–221.
13. Brooks, W.S., Kwok, J.B., Halliday, G.M., et al. Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology 9 (2004), 1613–1617.
14. Tian, Y., Bassit, B., Chau, D., et al. An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production. Nat. Struct. Mol. Biol. 17 (2010), 151–158.
15. Janssen, J.C., Beck, J.A., Campbell, T.A., et al. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 28 (2003), 235–239.
16. Hori, Y., Hashimoto, T., Wakutani, Y., et al. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation. J. Biol. Chem. 16 (2007), 4916–4923.
17. Murakami, K., Irie, K., Morimoto, A., et al. Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. J. Biol. Chem. 278 (2003), 46179–46187.
18. Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B., et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4 (2001), 887–893.
19. Levy, E., Carman, M.D., Fernandez-Madrid, I.J., et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248 (1990), 1124–1126.
20. Wattendorff, A.R., Bots, G.T., Went, L.N., et al. Familial cerebral amyloid angiopathy presenting as recurrent cerebral haemorrhage. J. Neurol. Sci. 55 (1982), 121–135.
21. Wisniewski, T., Ghiso, J., Frangione, B., Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem. Biophys. Res. Commun., 180, 1991, 1528.
22. Grabowski, T.J., Cho, H.S., Vonsattel, J.P., et al. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 49 (2001), 697–705.
23. Van Nostrand, W.E., Melchor, J.P., Romanov, G., et al. Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. Ann. N. Y. Acad. Sci. 977 (2002), 258–265.
24. Tagliavini, F., Rossi, G., Padovani, A., et al. A new βPP mutation related to hereditary cerebral haemorrhage. Alzheimer's Rep., 2, 1999, S28.
25. Parsons, C.G., Danysz, W., Quack, G., Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology 38 (1993), 735–767.
26. Nakamura, S., Murayama, N., Noshita, T., et al. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801. Eur. J. Pharmacol. 548 (2006), 115–122.
27. Nyakas, C., Granic, I., Halmy, L.G., et al. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine. Behav. Brain Res. 221 (2011), 594–603.
28. Scholtzova, H., Wadghiri, Y.Z., Douadi, M., et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J. Neurosci. Res. 86 (2008), 2784–2791.
29. Alley, G.M., Bailey, J.A., Chen, D., et al. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J. Neurosci. Res. 88 (2010), 143–154.
30. Dong, H., Yuede, C.M., Coughlan, C., et al. Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology 33 (2008), 3226–3236.
31. Martinez-Coria, H., Green, K.N., Billings, L.M., et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am. J. Pathol. 176 (2010), 870–880.
32. Ito, K., Tatebe, T., Suzuki, K., et al. Memantine reduces the production of amyloid-β peptides through modulation of amyloid precursor protein trafficking. Eur. J. Pharmacol. 798 (2017), 16–25.
33. Murakami, K., Horikoshi-Sakuraba, Y., Murata, N., et al. Monoclonal antibody against the turn of the 42-residue amyloid β-protein at positions 22 and 23. ACS Chem. Neurosci. 1 (2010), 747–756.
34. Umeda, T., Ramser, E.M., Yamashita, M., et al. Intracellular amyloid β oligomers impair organelle transport and induce dendritic spine loss in primary neurons. Acta Neuropathol. Commun., 3, 2015, 51.
35. Taniguchi, S., Suzuki, N., Masuda, M., et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280 (2005), 7614–7623.
36. Kornhuber, J., Quack, G., Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. 195 (1995), 137–139.
37. Bateman, R.J., Xiong, C., Benzinger, T.L., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367 (2012), 795–804.
38. Toledo, J.B., Xie, S.X., Trojanowski, J.Q., et al. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126 (2013), 659–670.